Skip to main content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 2/2015

01-02-2015

Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients

Auteurs: Hong-Hwa Chen, William Tzu-Liang Chen, Hsin-Chung Lee, Jen-Kou Lin, Chuan-Yin Fang, Yenn-Hwei Chou, Peng-Chan Lin, Bo-Wen Lin, Chi-Chou Huang, Chung-Hung Yeh, Hsi-Hsien Hsu, Hung-Chang Chen, Wen-Chien Ting, Ming-Chin Yang, Elise Chia-Hui Tan

Gepubliceerd in: Quality of Life Research | Uitgave 2/2015

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients.

Methods

We conducted a prospective, open-label, observational, multicenter study from July 2008 to July 2011. The European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires was used to assess HRQoL before, during, and after treatment. The direct and indirect costs of adjuvant treatment were estimated from a specially prepared questionnaire, the National Health Insurance Research Database, and other published sources. We used propensity scoring to match samples between groups and performed multivariate analyses to adjust for differences in patient demographics and clinical characteristics.

Results

A total of 497 patients were enrolled, and 356 completed the surveys. Following propensity score matching, 239 patients were included in the analysis (122 in the capecitabine-based group, 117 in the 5-FU/LV-based group). Global HRQoL scores did not differ significantly between the two groups. However, compared to patients in the 5-FU/LV-based group, patients in the capecitabine-based group had less nausea and vomiting (mid-term, P = 0.024; final, P = 0.013), appetite loss (mid-term, P < 0.0001; final, P = 0.001), and fewer side effects from chemotherapy (mid-term, P = 0.017). In addition, the monthly cost of capecitabine-based therapy was lower than those of 5-FU/LV-based therapy [NT$31,895.46 (US$1063.18) vs. NT$79,159.24 (US$2638.64) per patient].

Conclusions

Capecitabine is a reasonable alternative and cost-effective treatment option under current conditions for patients with stage III colorectal cancer.
Literatuur
1.
go back to reference Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003). Cancer statistics, 2003. CA-A Cancer Journal for Clinicians, 53(1), 5–26. PubMedCrossRef Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003). Cancer statistics, 2003. CA-A Cancer Journal for Clinicians, 53(1), 5–26. PubMedCrossRef
2.
go back to reference Parkin, D. M. (2001). Global cancer statistics in the year 2000. Lancet Oncology, 2(9), 533–543. CrossRef Parkin, D. M. (2001). Global cancer statistics in the year 2000. Lancet Oncology, 2(9), 533–543. CrossRef
3.
go back to reference Health Promotion Administration, Ministry of Health and Welfare, Taiwan. (2013). Cancer Registry Annual Report, 2010. Health Promotion Administration, Ministry of Health and Welfare, Taiwan. (2013). Cancer Registry Annual Report, 2010.
4.
go back to reference Health Promotion Administration, Ministry of Health and Welfare, Taiwan. (2010). Cancer Registry Annual Report, 2008. Health Promotion Administration, Ministry of Health and Welfare, Taiwan. (2010). Cancer Registry Annual Report, 2008.
5.
go back to reference National Health Insurance Administration, Ministry of Health and Welfare, Taiwan. (2012). Statistical annual report of medical care, 2011. National Health Insurance Administration, Ministry of Health and Welfare, Taiwan. (2012). Statistical annual report of medical care, 2011.
6.
go back to reference Obrand, D. I., & Gordon, P. H. (1997). Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Diseases of the Colon and Rectum, 40(1), 15–24. PubMedCrossRef Obrand, D. I., & Gordon, P. H. (1997). Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Diseases of the Colon and Rectum, 40(1), 15–24. PubMedCrossRef
7.
go back to reference Midgley, R., & Kerr, D. J. (2005). Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nature Clinical Practice Oncology, 2(7), 364–369. PubMedCrossRef Midgley, R., & Kerr, D. J. (2005). Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nature Clinical Practice Oncology, 2(7), 364–369. PubMedCrossRef
8.
go back to reference Van Cutsem, E., Dicato, M., Wils, J., Cunningham, D., Diaz-Rubio, E., Glimelius, B., et al. (2002). Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). European Journal of Cancer, 38(11), 1429–1436. PubMedCrossRef Van Cutsem, E., Dicato, M., Wils, J., Cunningham, D., Diaz-Rubio, E., Glimelius, B., et al. (2002). Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). European Journal of Cancer, 38(11), 1429–1436. PubMedCrossRef
9.
go back to reference Labianca, R., Marsoni, S., Pancera, G., Torri, V., Zaniboni, A., Erlichman, C., et al. (1995). Efficacy of adjuvant fluorouracil and folinic acid in colon-cancer. Lancet, 345(8955), 939–944. CrossRef Labianca, R., Marsoni, S., Pancera, G., Torri, V., Zaniboni, A., Erlichman, C., et al. (1995). Efficacy of adjuvant fluorouracil and folinic acid in colon-cancer. Lancet, 345(8955), 939–944. CrossRef
10.
go back to reference OConnell, M. J., Mailliard, J. A., Kahn, M. J., MacDonald, J. S., Haller, D. G., Mayer, R. J., et al. (1997). Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. Journal of Clinical Oncology, 15(1), 246–250. OConnell, M. J., Mailliard, J. A., Kahn, M. J., MacDonald, J. S., Haller, D. G., Mayer, R. J., et al. (1997). Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. Journal of Clinical Oncology, 15(1), 246–250.
11.
go back to reference Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., et al. (1999). Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: Results from national surgical adjuvant breast and bowel project C-04. Journal of Clinical Oncology, 17(11), 3553–3559. PubMed Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., et al. (1999). Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: Results from national surgical adjuvant breast and bowel project C-04. Journal of Clinical Oncology, 17(11), 3553–3559. PubMed
12.
go back to reference Arkenau, H. T., Bermann, A., Rettig, K., Strohmeyer, G., Porschen, R., & Arbeitsgemeinschaft Gastrointestinale Onkologie. (2003). 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Annals of Oncology, 14(3), 395–399. PubMedCrossRef Arkenau, H. T., Bermann, A., Rettig, K., Strohmeyer, G., Porschen, R., & Arbeitsgemeinschaft Gastrointestinale Onkologie. (2003). 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Annals of Oncology, 14(3), 395–399. PubMedCrossRef
13.
go back to reference Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology, 15(1), 110–115. PubMed Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology, 15(1), 110–115. PubMed
14.
go back to reference Pfeiffer, P., Mortensen, J. P., Bjerregaard, B., Eckhoff, L., Schonnemann, K., Sandberg, E., et al. (2006). Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. European Journal of Cancer, 42(16), 2738–2743. PubMedCrossRef Pfeiffer, P., Mortensen, J. P., Bjerregaard, B., Eckhoff, L., Schonnemann, K., Sandberg, E., et al. (2006). Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. European Journal of Cancer, 42(16), 2738–2743. PubMedCrossRef
15.
go back to reference Twelves, C., Gollins, S., Grieve, R., & Samuel, L. (2006). A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of Oncology, 17(2), 239–245. PubMedCrossRef Twelves, C., Gollins, S., Grieve, R., & Samuel, L. (2006). A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of Oncology, 17(2), 239–245. PubMedCrossRef
16.
go back to reference Guyatt, G. H., Ferrans, C. E., Halyard, M. Y., Revicki, D. A., Symonds, T. L., Varricchio, C. G., et al. (2007). Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clinic Proceedings, 82(10), 1229–1239. PubMedCrossRef Guyatt, G. H., Ferrans, C. E., Halyard, M. Y., Revicki, D. A., Symonds, T. L., Varricchio, C. G., et al. (2007). Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clinic Proceedings, 82(10), 1229–1239. PubMedCrossRef
17.
go back to reference Segalla, J. G. M., Van Eyll, B., Federico, M. H. H., Skare, N. G., Franke, F. A., Perdicaris, M. R., et al. (2008). Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine. Clinical Colorectal Cancer, 7(2), 126–133. PubMedCrossRef Segalla, J. G. M., Van Eyll, B., Federico, M. H. H., Skare, N. G., Franke, F. A., Perdicaris, M. R., et al. (2008). Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine. Clinical Colorectal Cancer, 7(2), 126–133. PubMedCrossRef
18.
go back to reference Ward, S. E., Kaltenthaler, E., Cowan, J., Marples, M., Orr, B., & Seymour, M. T. (2006). The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. British Journal of Cancer, 95(1), 27–34. PubMedCentralPubMedCrossRef Ward, S. E., Kaltenthaler, E., Cowan, J., Marples, M., Orr, B., & Seymour, M. T. (2006). The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. British Journal of Cancer, 95(1), 27–34. PubMedCentralPubMedCrossRef
19.
go back to reference Hsu, T. C., Chen, H. H., Yang, M. C., Wang, H. M., Chuang, J. H., Jao, S. W., et al. (2011). Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan. Value in Health, 14(5), 647–651. PubMedCrossRef Hsu, T. C., Chen, H. H., Yang, M. C., Wang, H. M., Chuang, J. H., Jao, S. W., et al. (2011). Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan. Value in Health, 14(5), 647–651. PubMedCrossRef
20.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N., et al. (1993). The European-Organization-for-Research-and-Treatment-of-Cancer Qlq-C30—a quality-of-life instrument for use in international clinical-trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. PubMedCrossRef Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N., et al. (1993). The European-Organization-for-Research-and-Treatment-of-Cancer Qlq-C30—a quality-of-life instrument for use in international clinical-trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. PubMedCrossRef
21.
go back to reference Sprangers, M. A. G., te Velde, A., Aaronson, N. K., & European Org Res Treatment Canc Study Grp, Q. (1999). The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Journal of Cancer, 35(2), 238–247. PubMedCrossRef Sprangers, M. A. G., te Velde, A., Aaronson, N. K., & European Org Res Treatment Canc Study Grp, Q. (1999). The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Journal of Cancer, 35(2), 238–247. PubMedCrossRef
22.
go back to reference Law, C. C., Tak Lam, W. W., Fu, Y. T., Wong, K. H., Sprangers, M. A., & Fielding, R. (2008). Validation of the Chinese version of the EORTC colorectal cancer-specific quality-of-life questionnaire module (QLQ-CR38). Journal of Pain Symptom Management, 35(2), 203–213. PubMedCrossRef Law, C. C., Tak Lam, W. W., Fu, Y. T., Wong, K. H., Sprangers, M. A., & Fielding, R. (2008). Validation of the Chinese version of the EORTC colorectal cancer-specific quality-of-life questionnaire module (QLQ-CR38). Journal of Pain Symptom Management, 35(2), 203–213. PubMedCrossRef
23.
go back to reference Uwer, L., Rotonda, C., Guillemin, F., Miny, J., Kaminsky, M. C., Mercier, M., et al. (2011). Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer. Health and Quality of Life Outcomes, 9, 70. PubMedCentralPubMedCrossRef Uwer, L., Rotonda, C., Guillemin, F., Miny, J., Kaminsky, M. C., Mercier, M., et al. (2011). Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer. Health and Quality of Life Outcomes, 9, 70. PubMedCentralPubMedCrossRef
24.
go back to reference Fayers, P. M., Aaronson, A. N., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: EORTC. Fayers, P. M., Aaronson, A. N., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: EORTC.
25.
go back to reference Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., Norman, G. R., & Clinical Significance Consensus Meeting Group. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77(4), 371–383. PubMedCrossRef Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., Norman, G. R., & Clinical Significance Consensus Meeting Group. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77(4), 371–383. PubMedCrossRef
26.
go back to reference Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144. PubMed Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144. PubMed
27.
go back to reference Directorate-General of Budget, Accounting and Statistics, Executive Yuan, Taiwan. (2010). Report on the the Manpower Utilization Survey. Directorate-General of Budget, Accounting and Statistics, Executive Yuan, Taiwan. (2010). Report on the the Manpower Utilization Survey.
28.
go back to reference Rosenbaum, P. R., & Rubin, D. B. (1985). Constructing a control-group using multivariate matched sampling methods that incorporate the propensity score. American Statistician, 39(1), 33–38. Rosenbaum, P. R., & Rubin, D. B. (1985). Constructing a control-group using multivariate matched sampling methods that incorporate the propensity score. American Statistician, 39(1), 33–38.
29.
go back to reference Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., et al. (2005). Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine, 352(26), 2696–2704. PubMedCrossRef Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., et al. (2005). Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine, 352(26), 2696–2704. PubMedCrossRef
30.
go back to reference Lopatriello, S., Negrini, C., Amoroso, D., Donati, S., Alabiso, O., Fornasiero, A., et al. (2008). Metastatic colorectal cancer: medical costs of first line infusional 5-fluorouracil or oral capecitabine in Italian patients. Value in Health, 11(6), A479–A479. CrossRef Lopatriello, S., Negrini, C., Amoroso, D., Donati, S., Alabiso, O., Fornasiero, A., et al. (2008). Metastatic colorectal cancer: medical costs of first line infusional 5-fluorouracil or oral capecitabine in Italian patients. Value in Health, 11(6), A479–A479. CrossRef
31.
go back to reference Van Cutsem, E., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., et al. (2004). Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. British Journal of Cancer, 90(6), 1190–1197. PubMedCentralPubMedCrossRef Van Cutsem, E., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., et al. (2004). Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. British Journal of Cancer, 90(6), 1190–1197. PubMedCentralPubMedCrossRef
32.
go back to reference Twelves, C., Boyer, M., Findlay, M., Cassidy, J., Weitzel, C., Baker, C., et al. (2001). Capecitabine (Xeloda (TM)) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer, 37(5), 597–604. PubMedCrossRef Twelves, C., Boyer, M., Findlay, M., Cassidy, J., Weitzel, C., Baker, C., et al. (2001). Capecitabine (Xeloda (TM)) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer, 37(5), 597–604. PubMedCrossRef
33.
go back to reference Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., et al. (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. Journal of Clinical Oncology, 19(21), 4097–4106. PubMed Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., et al. (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. Journal of Clinical Oncology, 19(21), 4097–4106. PubMed
34.
go back to reference Cassidy, J., Douillard, Y., Twelves, C., McKendrick, J. J., Scheithauer, W., Bustova, I., et al. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. British Journal of Cancer, 94(8), 1122–1129. PubMedCentralPubMedCrossRef Cassidy, J., Douillard, Y., Twelves, C., McKendrick, J. J., Scheithauer, W., Bustova, I., et al. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. British Journal of Cancer, 94(8), 1122–1129. PubMedCentralPubMedCrossRef
35.
go back to reference Twelves, C. J. (2006). Xeloda (R) in adjuvant colon cancer therapy (X-ACT) trial: Overview of efficacy, safety, and cost-effectiveness. Clinical Colorectal Cancer, 6(4), 278–287. PubMedCrossRef Twelves, C. J. (2006). Xeloda (R) in adjuvant colon cancer therapy (X-ACT) trial: Overview of efficacy, safety, and cost-effectiveness. Clinical Colorectal Cancer, 6(4), 278–287. PubMedCrossRef
36.
go back to reference Chu, E., Schulman, K. L., Zelt, S., & Song, X. (2009). Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer, 115(7), 1412–1423. PubMedCrossRef Chu, E., Schulman, K. L., Zelt, S., & Song, X. (2009). Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer, 115(7), 1412–1423. PubMedCrossRef
37.
go back to reference Chu, E., Schulman, K. L., McKenna, E. F, Jr, & Cartwright, T. (2010). Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: A cost comparison. Clinical Colorectal Cancer, 9(4), 229–237. PubMedCrossRef Chu, E., Schulman, K. L., McKenna, E. F, Jr, & Cartwright, T. (2010). Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: A cost comparison. Clinical Colorectal Cancer, 9(4), 229–237. PubMedCrossRef
38.
go back to reference Chu, E., Shi, N. W., Wei, W. H., Bendell, J. C., & Cartwright, T. (2009). Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology, 77(3–4), 244–253. PubMedCrossRef Chu, E., Shi, N. W., Wei, W. H., Bendell, J. C., & Cartwright, T. (2009). Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology, 77(3–4), 244–253. PubMedCrossRef
39.
go back to reference Schmoll, H. J., Cartwright, T., Tabernero, J., Nowacki, M. P., Figer, A., Maroun, J., et al. (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. Journal of Clinical Oncology, 25(1), 102–109. PubMedCrossRef Schmoll, H. J., Cartwright, T., Tabernero, J., Nowacki, M. P., Figer, A., Maroun, J., et al. (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. Journal of Clinical Oncology, 25(1), 102–109. PubMedCrossRef
40.
go back to reference Conroy, T., Hebbar, M., Bennouna, J., Ducreux, M., Ychou, M., Lledo, G., et al. (2010). Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. British Journal of Cancer, 102(1), 59–67. PubMedCentralPubMedCrossRef Conroy, T., Hebbar, M., Bennouna, J., Ducreux, M., Ychou, M., Lledo, G., et al. (2010). Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. British Journal of Cancer, 102(1), 59–67. PubMedCentralPubMedCrossRef
Metagegevens
Titel
Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients
Auteurs
Hong-Hwa Chen
William Tzu-Liang Chen
Hsin-Chung Lee
Jen-Kou Lin
Chuan-Yin Fang
Yenn-Hwei Chou
Peng-Chan Lin
Bo-Wen Lin
Chi-Chou Huang
Chung-Hung Yeh
Hsi-Hsien Hsu
Hung-Chang Chen
Wen-Chien Ting
Ming-Chin Yang
Elise Chia-Hui Tan
Publicatiedatum
01-02-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 2/2015
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-014-0773-x

Andere artikelen Uitgave 2/2015

Quality of Life Research 2/2015 Naar de uitgave